report consesnu result establish
conserv consensu guid headwind
trial enrol expect slow soliri sale growth
note soliri sale grew demand trend
remain stabl core indic even account headwind
partli off-set fx tailwind believ robust uptak gmg
doubl number treat patient sinc provid
ad growth lead management beat rais throughout
result expect report total revenu
y/i vs consensu driven volum growth y/i
benefit favor order time trial
enrol provid headwind bottom line lower cogs/
 d/tax expens drove non-gaap ep y/i ahead
consensu
soliri q/q sale came consensu
vs y/i volum growth growth stronger
 y/i vs y/i ex-u sale impact
order favor time headwind
trial enrol manag note continu
see strength pnh ahu patient identif point
given time gmg approv launch minim impact
soliri sale seen gmg
strensiq q/q vs consensu sale
continu grow across germani japan larg due new
patient identif effort new fund agreement canada
ad recent establish uk franc israel
kanuma sale q/q came ahead consensu vs
base primarili favor order ex-u tender
market previous defer revenu less benefit
sale line consensu estim would shown
mute sale growth q/q lab test initi began
middl continu expand test patient
higher risk lal-d nash/nafld famili
hypercholerolemia increasingli receiv test within ex-u
estim rais
estim lower
estim lower
tr target
provid new guidanc call full-year revenu growth mid-point
vs consensu non-gaap ep expect
rang y/i mid-point vs consensu see figur compani guid
headwind price headwind soliri
metabol fx tailwind addit tax rate guidanc
higher previou year due recent tax reform
acknowledg new manag team establish lower baselin believ
like beat rais estim expect grow revenu gmg
off-set larg portion headwind
revenu recognit recogn hurt y/i growth moreov
tender order came repeat therefor y/i revenu growth
like singe-digit rang manag guid oper margin
guidanc single-digit y/i ep growth
pois re-acceler y/i revenu growth like
high teen manag guid oper margin guidanc y/
ep growth full year guidanc improv soliri sale mg see
lower impact trial enrol
growth soliri y/i volum growth high-singl digit headwind price
row hit heavili due price registr brazil late
enrol compani also note exclud trial enrol
price headwind revenu growth would mid-teen
headwind expect continu two pnh studi call
patient stay extend treatment regimen drug registr approv expect
protocol allow trial particip continu receiv treatment
henc purchas soliri least anoth year adult pediatr
ahu trial still recruit patient believ headwind soliri continu indic
well
y/i growth expect slower due trial enrol
much along result larger revenu impact contrast
impact trial reduc result rapid y/i growth
reflect current trend increas soliri ww sale estim
soliri launch mg manag top prioriti manag highli focus
execut success first year launch germani japan note
ambit gmg launch best alexion soliri launch gener
revenu pnh ahu level estim target patient popul
geographi patient germani japan
manag point commerci live coverag
soliri mg
gmg treatment popul growth rapid manag note patient current
receiv soliri gmg patient end moreov manag note
enrol gmg onesourc program offer alexion provid educ
assist access soliri patient patient end
holiday behind us patient/physician educ effort underway believ growth
pois continu
page
new patient investig alexion see onesourc part
trial indic robust earli adopt soliri mg patient mani
sever run option commun neurologist
drive growth mg via field field team engag educ
neurologist neuromuscular specialist mani limit knowledg complement
benefit soliri treatment preserv neuromuscular junction base
encourag commentari earli launch dynam gmg still puzzl
guidanc reflect confid gmg launch said work field
team underway manag expect soliri revenu improv singl digit growth
high teen growth
metabol expect gener mid-point primarili
new patient add due diseas educ diagnost initi begin gener return
price headwind guid manag due metabol
manag expect continu geograph expans strensiq note
still earli strensiq launch trajectori anticip substanti growth futur expand
diseas diagnost initi expect growth acceler throughout
manag note regard kanuma one five key initi serv
patient lal-d expand addit countri serv addit
patient itali spain israel netherland follow recent fund agreement
reflect current trend lower strensiq ww sale estim
kanuma ww sale estim
manag reiter belief crown jewel goal establish
new standard care pnh ahu
report data posit compani file regulatori approv eu
japan possibl commerci note patient
enrol trial patient provid tailwind transit
clinic trial commerci drug upon approv
expect complet data treatment-na pediatr ahu
popul phase enrol on-going
subq expect enter clinic pk-base bridg studi use
high concentr expect support registr pnh ahu
page
manag note current formul design weekli dose
investig use halozym enhanz technolog creat subq formul suitabl
dose
studi gmg registr igan poc expect begin later
reflect commerci trend lower revenu estim
respect
non-gaap ep estim revis
adjust lt tax rate assumpt
lower npv-deriv pt
page
page
producteventtimingdata phase prevent trial relaps nmosd updat patent coverag enrol phase treatment-na adolesc adult ahu studi data phase treatment-nav pnh studi data phase soliris-switch pnh studi data phase treatment-nav adolesc adult ahu studi singl pk-base phase bridg studi weekli sub-q phase studi second-gen sub-q registr studi proof-of-concept studi immunoglobulin nephropathi eu japan regulatori submiss decis approv european countri outsid approv european countri outsid strh analysi compani reportscompl franchisemetabol inc
page
estim estim changestrhactualconsensusa vs street mm except per share diff mm except per share data priorcurr chang chang mm except per share data priorcurr chang total total total total total total total total total opex opex opex strh analysi consensu provid last updat perform inc
page
soliri yoy yoy metabol franchis gross oper oper incom non-gaap tax incom loss net incom net gaap yoy ep exclud stock-comp item strh analysi compani report last updat mm inc
biotechnolog compani engag research develop
commerci life-transform therapeut treat patient sever ultra-rar diseas
product offer fall two broad franchis complement metabol core
alexion complement franchis soliri world first termin complement inhibitor approv
treatment patient paroxysm nocturn hemoglobinuria pnh patient atyp
hemolyt urem syndrom ahu two approv product metabol franchis includ
strensiq enzym replac therapi ert approv hypophosphotasia
kanuma also ert approv lysosom acid lipas defici lal-d alexion found
headquart cheshir ct
alexion premier orphan disease-focus biotech two franchis complement
metabol year experi complement biolog flagship product soliri
standard-of-car two ultra-rar blood disord pnh ahu deep complement pipelin
slate extend domin next decad expect share outperform
potenti upward earn revis clinical/regulatori newsflow
valuat risk
pt base sum-of-the-part sotp net-present-valu npv analysi
includ estim npv soliri cash flow pnh ahu soliri cash flow mg probability-
adjust strensiq cash flow kanuma cash flow lal-d compani current
net cash posit use discount rate termin growth rate believ
appropri compani similar alexion base assumpt npv suggest
fair valu contribut pipelin candid model leav substanti
room potenti upsid
alexion busi larg depend commerci success soliri strensiq kanuma
product could face intens competit newer emerg therapeut products/
class unexpect advers event could hamper accept among physician
patient
alexion launch strensiq kanuma earli stage new sale market
distribut strategi capabl metabol portfolio yet proven market size
ultra-orphan indic lal-d smaller project anticip futur sale
could significantli impact
drug-pric strategi come increas scrutini lawmak far biotech
compani abl take frequent price increas product could moder
go forward ou territori government-sponsor healthcar system pay healthcar
cost product could subject increas price reimburs pressur due price control
impos govern mani countri
alexion growth conting novel product continu label
expans new indic soliri rmg/nmo could face clinic regulatori
setback prospect growth driver critic long-term success alexion
alexion busi signific exposur fluctuat foreign currenc exchang rate
approxim two-third revenu gener outsid us past year addit alexion
could face signific challeng south america brazil argentina commod depend
economi given recent turmoil oil commod
yatin suneja herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
